Truist raised the firm’s price target on Fresenius Medical (FMS) to $30 from $25 and keeps a Hold rating on the shares as part of a broader research note on Health Care Services. The firm is updating its models to reflect Q1 results and updated guidance on select names, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care (FMS) Discloses Q2 Dividend: What Shareholders Should Know
- Fresenius Medical Care Q1 2025 Earnings Call Highlights
- Fresenius Medical Care: Balanced Outlook with Hold Rating Amid Mixed Growth Signals
- Fresenius Medical Care Reports Strong Q1 2025 Earnings
- Fresenius Medical Care AG Announces Q1 2025 Financial Results and EUR 600 Million Note Issuance